RightFit
RecruitingPhase 2

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 70 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests the safety of D-2570 and how well it works for plaque psoriasis, a skin condition that causes thick, scaly patches. It is for people with moderate to severe plaque psoriasis.

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You have been diagnosed with plaque psoriasis and have had no major flare-ups for at least 6 months before signing the study consent form.
  • Psoriasis covers at least 10% of your body. Your PASI score, which measures how much skin is affected and how severe it is, is at least 12. Your PGA score, a doctor's rating of severity, is at least 3.
  • Your lab test results are within normal ranges.

Who can't join

  • You have a current or past health condition listed in the study rules that the study doctor thinks would interfere with study checks.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent * Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3. * Within normal ranges of laboratory assessments Exclusion Criteria: * Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator

Study sites (20)

AL

AZ

CA

FL

GA

ID

IN

KY

OH

PA

TX